Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Savara Inc.
Coronavirus Update: Neurimmune, Ethris, Fujifilm, Brii In New Bids Against COVID-19, Reata, Ionis Delay Studies
Neurimmune and Ethris partner on inhaled therapy. Reata, Ionis and others delay trials, Brii announces China antibody alliance, Fujifilm starts favipiravir trials. World's largest trial for health workers starts.
Italfarmaco and Neupharma plan to collaborate on the development of a new inhaled formulation of a Gram-positive targeted antibiotic for MRSA infections in cystic fibrosis.
Orphan lung disease firm tries to sell Phase III setback in aPAP as a “successful failed study” but investors disagree, cutting Savara’s share price by three-quarters. Biotech hopes to talk with regulators after deeper dive into dataset.
Merck unveiled Phase III data showing efficacy in hospital-acquired bacterial pneumonia, but branded drugs with this indication currently have not scored significant sales.
- Drug Delivery
- Nanotechnology, Chips, etc.
- Other Names / Subsidiaries
- Serendex ApS, Mast Therapeutics, Inc.
- SD Pharmaceuticals Inc
- Savara ApS
- Synthrx, Inc.
- Aires Pharmaceuticals, Inc.
- Savara Pharmaceuticals